Cambium Bio (ASX:CMB) Moat Score: 0/10 (As of Jun. 27, 2026)


ASX:CMB Cambium Bio Ltd ASX:CMB
35 GF Score
Price A$0.42
! 4 Warning Signs
View Full Analysis

What is Cambium Bio Moat Score?

Cambium Bio has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Cambium Bio has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Cambium Bio might have No Moat - No discernible moat.

Cambium Bio  (ASX:CMB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Cambium Bio Moat Score Related Terms

ASX:CMB
35GF Score
Cambium Bio Ltd ASX:CMB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cambium Bio Business Description

Address Unit 2.06, 31 Lexington Drive, Bella Vista, NSW, AUS, 2153
Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate, Elate Ocular, is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.
35GF Score

Get the complete analysis for ASX:CMB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.42
Price